Credit Suisse Upgrades Merck (MRK) to Outperform
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Credit Suisse upgraded Merck (NYSE: MRK) from Neutral to Outperform with a price target of $73.00 following news Friday that Bristol-Myers' CheckMate-026 (CM-026) Study for Opdivo in 1st line non-small cell lung cancer (NSCLC) missed its primary endpoint.
Analyst Vamil Divan commented, "Friday's developments help answer one of the main concerns we had on MRK as we struggled to see where they would find near to mid-term growth in the face of patent loss for Vytorin/Zetia, biosimilar competition for Remicade and increasing competition for Januvia/Janumet. Our MRK sales estimates increase by $1.6-$2.4 Bn for the next few years and our EPS estimates move to $4.06- $5.00 from $3.70-$4.45, suggesting a 2015-2019 EPS CAGR of 8.6%. Our DCF for MRK increases to $72. Our blended target price of 75% DCF/25% relative, with the relative based off of 18.0x our new 2017 EPS of $4.06, is $73. We acknowledge the lack of a CTLA-4 antibody could eventually limit MRK's potential in combination therapy. However, Keytruda will be a dominant player in monotherapy and MRK has quietly been developing a broad range of combination approaches as well."
Shares of Merck closed at $63.86 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Raises Price Target on Citizens Financial Group (CFG) Following 3Q EPS Beat
- Seaport Global Securities Upgrades Tutor Perini Corporation (TPC) to Buy
- KLR Group Cuts Price Target on Southwestern Energy (SWN) to $14
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change, Upgrades
Related EntitiesCredit Suisse
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!